Biostream Receives FDA Breakthrough Device Designation for a Urine Test to Aid the Diagnosis of Normal Pressure Hydrocephalus
Biostream's test measures proteins in a urine sample to help clinicians distinguish idiopathic normal pressure hydrocephalus (iNPH), a treatable cause of walking, memory and bladder problems, from Alzheimer's disease and other neurodegenerative disorders
HAIFA, Israel, Nov. 18, 2026 /PRNewswire/ -- Biostream, a company developing urine-based biomarker diagnostics for neurological care, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to its urine test for iNPH on November 12, 2026. The test measures a panel of proteins and applies a proprietary algorithm to generate a probability score.
The test is intended for use by healthcare professionals, together with clinical assessment, to aid in the diagnosis of iNPH and its differentiation from Alzheimer's disease and other neurodegenerative disorders in patients aged 60 and older with signs and symptoms suggestive of NPH.
FDA's Breakthrough Devices Program is intended to give patients more timely access to medical devices that may provide more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions. Designated devices receive priority review and more interactive engagement with FDA during development.
"Too many people with normal pressure hydrocephalus are told their symptoms are Alzheimer's or simply old age, when a treatable condition is behind them," said Dr. Meital Segev Bar, Co-founder and CEO of Biostream. "Breakthrough Device Designation recognizes this unmet need and the potential of a simple urine test to change how these patients are identified. We look forward to working closely with FDA as we advance our test toward clinical validation."
Normal pressure hydrocephalus is a build-up of cerebrospinal fluid in the brain that causes walking difficulties, memory and thinking problems, and loss of bladder control. Unlike most causes of dementia-like symptoms, it can often be treated: shunt surgery to drain the excess fluid can bring substantial improvement, especially when performed early. Yet iNPH is frequently mistaken for Alzheimer's disease, Parkinson's disease or normal aging. Studies estimate that it affects about 2-4% of people aged 65 and older, and the Hydrocephalus Association reports that more than 80% of patients are unrecognized or untreated.
Confirming the diagnosis today relies on brain imaging and invasive spinal fluid tests, such as a lumbar tap test, which are available mainly at specialized centers. Biostream's test is designed to add objective, biology-based information from a urine sample, to help clinicians identify patients who may have iNPH and should be considered for further evaluation.
Biostream plans a prospective clinical validation study at U.S. academic medical centers during 2027.
About the test
Biostream's iNPH test is a urine test that measures a panel of proteins and applies a proprietary algorithm to help clinicians evaluate patients with suspected normal pressure hydrocephalus. It is an investigational device and is not currently available for sale in the United States. Breakthrough Device Designation is not FDA clearance or approval and does not guarantee marketing authorization.
About Biostream
Biostream develops urine-based biomarker diagnostics for neurological care. Founded in 2025, the company combines urinary proteomics with machine learning to give clinicians objective, non-invasive tools for diagnosing and managing neurological disorders. Its first product addresses normal pressure hydrocephalus.
Contact: [email protected]
SOURCE BioStream

Share this article